Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05822427 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study

StatusRecruiting
PhaseNot specified
Started2020-08-25
View on ClinicalTrials.gov ↗
The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Product in an Imugene Clinical Study. The main questions it aims to answer are: * What are the frequency, severity, duration, and outcome of clinically significant Clinical Events of Interest (CEI)? * What is the duration of response and overall survival time after taking an allogeneic CAR T-Cell product on an Imugene clinical study? Participants will have a yearly visit either face to face or remotely for up to 15 years to check for CEI.

Amendment record

Amended once since 2023-04-10. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2025-05-11
Amendment Study Identification, Study Status, Sponsor/Collaborators, Oversight, Study Description, Conditions, Study Design, Outcome Measures, Eligibility, Contacts/Locations v1
2023-04-10
Original filing
Trial Details
NCT Number NCT05822427
Lead Sponsor Imugene Limited
Conditions Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
Enrollment 75 participants
Start Date 2020-08-25
Primary Completion 2039-12 (estimated)
Study Completion 2039-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-14